Actavis gets US antitrust nod for Allergan buyout
MLex Summary: Drugmaker Actavis said Monday that the US Federal Trade Commission has granted early termination of the company's plan to acquire Botox provider Allergan for approximately $66 billion in cash and stock. Statement follows...To view the full article, register now.
Already a subscriber? Click here to view full article